CDIO (Cardio Diagnostics Holdings) Enterprise Value: $-1.90 Mil (As of Jul. 30, 2026) ***

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CDIO Cardio Diagnostics Holdings Inc CDIO
49 GF Score
Price $1.57
GF Value $2.77
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Cardio Diagnostics Holdings Enterprise Value?

Cardio Diagnostics Holdings CDIO +0.15% 49 Enterprise Value is $-1.90 Mil as of Jul. 30, 2026. GuruFocus rates CDIO with a GF Score™ of 49/100 and a GF Value™ of $2.77 (Possible Value Trap). The stock has 3 warning signs investors should review.

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cardio Diagnostics Holdings's Enterprise Value is $-1.90 Mil. Cardio Diagnostics Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-6.64 Mil. Therefore, Cardio Diagnostics Holdings's EV-to-EBIT ratio for today is 0.29.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Cardio Diagnostics Holdings's Enterprise Value is $-1.90 Mil. Cardio Diagnostics Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-6.27 Mil. Therefore, Cardio Diagnostics Holdings's EV-to-EBITDA ratio for today is 0.30.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Cardio Diagnostics Holdings's Enterprise Value is $-1.90 Mil. Cardio Diagnostics Holdings's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $0.02 Mil. Therefore, Cardio Diagnostics Holdings's EV-to-Revenue ratio for today is -111.76.

EV-to-OCF is calculated as Enterprise Value divided by its Cash Flow from Operations. As of today, Cardio Diagnostics Holdings's Enterprise Value is $-1.90 Mil. Cardio Diagnostics Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-5.89 Mil. Therefore, Cardio Diagnostics Holdings's EV-to-OCF ratio for today is 0.32.

EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Cardio Diagnostics Holdings's Enterprise Value is $-1.90 Mil. Cardio Diagnostics Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-6.32 Mil. Therefore, Cardio Diagnostics Holdings's EV-to-FCF ratio for today is 0.30.

*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.


Cardio Diagnostics Holdings  (NAS:CDIO) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Cardio Diagnostics Holdings's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-1.900/-6.638
=0.29

Cardio Diagnostics Holdings's current Enterprise Value is $-1.90 Mil.
Cardio Diagnostics Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.64 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Cardio Diagnostics Holdings's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=-1.900/-6.27
=0.30

Cardio Diagnostics Holdings's current Enterprise Value is $-1.90 Mil.
Cardio Diagnostics Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.27 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Cardio Diagnostics Holdings's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=-1.900/0.017
=-111.76

Cardio Diagnostics Holdings's current Enterprise Value is $-1.90 Mil.
Cardio Diagnostics Holdings's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02 Mil.

4. EV-to-OCF is calculated as Enterprise Value divided by its Cash Flow from Operations.

Cardio Diagnostics Holdings's EV-to-OCF for today is:

EV-to-OCF=Enterprise Value (Today)/Cash Flow from Operations (TTM)
=-1.900/-5.888
=0.32

Cardio Diagnostics Holdings's current Enterprise Value is $-1.90 Mil.
Cardio Diagnostics Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.89 Mil.

5. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.

Cardio Diagnostics Holdings's EV-to-FCF for today is:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-1.900/-6.324
=0.30

Cardio Diagnostics Holdings's current Enterprise Value is $-1.90 Mil.
Cardio Diagnostics Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.32 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cardio Diagnostics Holdings Enterprise Value Related Terms


Cardio Diagnostics Holdings Enterprise Value Historical Data

* Premium members only.

The historical data trend for Cardio Diagnostics Holdings's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardio Diagnostics Holdings Enterprise Value Chart

Cardio Diagnostics Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Enterprise Value
Get a 7-Day Free Trial 0.00 6.81 51.15 35.26 0.53

Cardio Diagnostics Holdings Quarterly Data
Mar21 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.32 -1.08 1.22 0.53 -0.77

CDIO vs ERNA, LABT, JAGX: Enterprise Value Comparison

For the Biotechnology subindustry, Cardio Diagnostics Holdings's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardio Diagnostics Holdings Enterprise Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardio Diagnostics Holdings's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Cardio Diagnostics Holdings's Enterprise Value falls into.


CDIO
49GF Score
Cardio Diagnostics Holdings Inc CDIO
Enterprise Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cardio Diagnostics Holdings Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Cardio Diagnostics Holdings's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as

Cardio Diagnostics Holdings's Enterprise Value for the quarter that ended in Mar. 2026 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Enterprise Value →
What does a Enterprise Value of $-1.90 Mil mean?
Cardio Diagnostics Holdings (CDIO) has a Enterprise Value of $-1.90 Mil as of Jul. 30, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Cardio Diagnostics Holdings and its competitors.
Is Cardio Diagnostics Holdings' Enterprise Value too high?
Cardio Diagnostics Holdings' current Enterprise Value is $-1.90 Mil. Overall, Cardio Diagnostics Holdings has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cardio Diagnostics Holdings' Enterprise Value compare to ERNA and LABT?
Cardio Diagnostics Holdings' Enterprise Value of $-1.90 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Cardio Diagnostics Holdings and its competitors. Cardio Diagnostics Holdings's current Enterprise Value is $-1.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardio Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Cardio Diagnostics Holdings (CDIO) is currently considered Possible Value Trap. The stock's GF Value™ is $2.77, compared to a current price of $1.57 — trading 43.3% below its estimated fair value. The current Enterprise Value is $-1.90 Mil. Cardio Diagnostics Holdings' overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Cardio Diagnostics Holdings (CDIO), the current Enterprise Value is $-1.90 Mil as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cardio Diagnostics Holdings (CDIO) Overvalued in 2026?

Based on GuruFocus' analysis, Cardio Diagnostics Holdings stock appears to be undervalued. The current stock price of $1.57 is trading 43.3% below its estimated GF Value™ of $2.77. GuruFocus considers Cardio Diagnostics Holdings to be Possible Value Trap.

Key valuation signals for CDIO:

  • Enterprise Value: $-1.90 Mil
  • GF Value™: $2.77 vs. price of $1.57 (43.3% below fair value)
  • GF Score™: 49/100 with 3 warning signs

No single metric tells the full story. See the CDIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cardio Diagnostics Holdings Business Description

Address 311 West Superior Street, Suite 444, Chicago, IL, USA, 60654
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
49GF Score

Get the complete analysis for CDIO

Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.57
Price
$2.77
GF Value